[go: up one dir, main page]

PE20120034A1 - Compuestos derivados de n-fenilpirimidin-2-amina - Google Patents

Compuestos derivados de n-fenilpirimidin-2-amina

Info

Publication number
PE20120034A1
PE20120034A1 PE2011001080A PE2011001080A PE20120034A1 PE 20120034 A1 PE20120034 A1 PE 20120034A1 PE 2011001080 A PE2011001080 A PE 2011001080A PE 2011001080 A PE2011001080 A PE 2011001080A PE 20120034 A1 PE20120034 A1 PE 20120034A1
Authority
PE
Peru
Prior art keywords
phenylpyrimidin
amine
compounds derived
cycloalkyl
aryl
Prior art date
Application number
PE2011001080A
Other languages
English (en)
Inventor
Heinz Stadtmueller
Ioannis Sapountzis
Original Assignee
Boehringer Ingelheim Int
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=42115425&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=PE20120034(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Boehringer Ingelheim Int filed Critical Boehringer Ingelheim Int
Publication of PE20120034A1 publication Critical patent/PE20120034A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/10—Antimycotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/46—Two or more oxygen, sulphur or nitrogen atoms
    • C07D239/47—One nitrogen atom and one oxygen or sulfur atom, e.g. cytosine
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D419/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen, oxygen, and sulfur atoms as the only ring hetero atoms
    • C07D419/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen, oxygen, and sulfur atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D493/00—Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system
    • C07D493/02—Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system in which the condensed system contains two hetero rings
    • C07D493/04—Ortho-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Hematology (AREA)
  • Virology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

SE REFIERE A UNA COMPUESTO DE FORMULA (1) DONDE: A ES CICLOALQUILO C3-C10, HETEROCICLOALQUILO C3-C8, ARILO C6-C15, HETEROARILO C5-C12 SUSTITUIDO O NO CON UNO O MAS R1; B ES UN SISTEMA DE ANILLOS CARBOCICLICO O HETEROBICICLICO C9-C11 SUSTITUIDO O NO CON UNO O MAS R2; X SE SELECCIONA ENTRE O, S Y CH2; R1 Y R2 SON CADA UNO H, ALQUILO C1-C6, CICLOALQUILO C3-C10, =O, =S, ENTRE OTROS; R3 ES H, HALOGENO, -ORc, -OCF3, -SRc, ENTRE OTROS; Rc ES H O UN RADICAL SELECCIONADO ENTRE ALQUILO C1-6, ARILO C6-10, ARILALQUILO C7-16, ENTRE OTROS. SON COMPUESTOS PREFERIDOS (2), (3), ENTRE OTROS. REFERIDA TAMBIEN A UNA COMPOSCION FARMACEUTICA. DICHOS COMPUESTOS SON INHIBIDORES DE LA TIROSINA QUINASA SIENDO UTILES EN EL TRATAMIENTO DE ENFERMEDADES RELACIONADAS CON PROLIFERACION CELULAR EXCESIVA O ANOMALIA
PE2011001080A 2008-11-24 2009-11-24 Compuestos derivados de n-fenilpirimidin-2-amina PE20120034A1 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP08169807 2008-11-24
EP09169654 2009-09-07

Publications (1)

Publication Number Publication Date
PE20120034A1 true PE20120034A1 (es) 2012-02-19

Family

ID=42115425

Family Applications (1)

Application Number Title Priority Date Filing Date
PE2011001080A PE20120034A1 (es) 2008-11-24 2009-11-24 Compuestos derivados de n-fenilpirimidin-2-amina

Country Status (26)

Country Link
US (4) US8846689B2 (es)
EP (1) EP2367800B9 (es)
JP (1) JP5622740B2 (es)
KR (1) KR101710058B1 (es)
CN (2) CN102292322B (es)
AP (1) AP2960A (es)
AR (1) AR074210A1 (es)
AU (1) AU2009317170B2 (es)
BR (1) BRPI0922801B1 (es)
CA (1) CA2744351C (es)
CL (1) CL2011001215A1 (es)
CO (1) CO6511283A2 (es)
EA (1) EA021997B1 (es)
EC (1) ECSP11011079A (es)
ES (1) ES2664499T3 (es)
GE (1) GEP20146072B (es)
IL (1) IL212814B (es)
MA (1) MA32811B1 (es)
MX (1) MX337116B (es)
MY (1) MY176944A (es)
NZ (1) NZ592925A (es)
PE (1) PE20120034A1 (es)
TN (1) TN2011000259A1 (es)
TW (1) TWI491605B (es)
UY (1) UY32259A (es)
WO (1) WO2010058032A2 (es)

Families Citing this family (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AR074209A1 (es) 2008-11-24 2010-12-29 Boehringer Ingelheim Int Derivados de pirimidina utiles para el tratamiento del cancer
TWI491605B (zh) 2008-11-24 2015-07-11 Boehringer Ingelheim Int 新穎化合物
US8933227B2 (en) 2009-08-14 2015-01-13 Boehringer Ingelheim International Gmbh Selective synthesis of functionalized pyrimidines
EP2464633A1 (en) 2009-08-14 2012-06-20 Boehringer Ingelheim International GmbH Regioselective preparation of 2-amino-5-trifluoromethylpyrimidine derivatives
US20120244141A1 (en) 2010-09-28 2012-09-27 Boehringer Ingelheim International Gmbh Stratification of cancer patients for susceptibility to therapy with PTK2 inhibitors
ES2691673T3 (es) * 2011-02-17 2018-11-28 Cancer Therapeutics Crc Pty Limited Inhibidores de Fak
CN103534240B (zh) * 2011-02-17 2015-12-09 癌症疗法Crc私人有限公司 选择性fak抑制剂
JPWO2013146963A1 (ja) * 2012-03-28 2015-12-14 武田薬品工業株式会社 複素環化合物
PL3043784T3 (pl) 2013-09-09 2019-10-31 Peloton Therapeutics Inc Etery arylowe i ich zastosowania
US10512626B2 (en) 2015-03-11 2019-12-24 Peloton Therapeautics, Inc. Compositions for use in treating glioblastoma
US10278942B2 (en) 2015-03-11 2019-05-07 Peloton Therapeutics, Inc. Compositions for use in treating pulmonary arterial hypertension
WO2016144825A1 (en) 2015-03-11 2016-09-15 Peloton Therapeutics, Inc. Aromatic compounds and uses thereof
US10155726B2 (en) 2015-03-11 2018-12-18 Peloton Therapeutics, Inc. Substituted pyridines and uses thereof
WO2016168510A1 (en) 2015-04-17 2016-10-20 Peloton Therapeutics, Inc. Combination therapy of a hif-2-alpha inhibitor and an immunotherapeutic agent and uses thereof
US20170066778A1 (en) * 2015-09-04 2017-03-09 Aunova Medchem LLC Solubility for target compounds
US20230145356A1 (en) 2019-11-18 2023-05-11 Inxmed (Nanjing) Co., Ltd. Use of fak inhibitor in preparation of drug for treating tumors having nras mutation
BR112022010319A2 (pt) * 2019-11-28 2022-08-16 Inxmed Nanjing Co Ltd Uso de bi853520 no tratamento de câncer
BR112022015150A2 (pt) 2020-02-05 2022-10-11 Inxmed Nanjing Co Ltd Combinação de bi853520 com fármacos quimioterápicos
US20230278985A1 (en) * 2020-08-03 2023-09-07 Inxmed (Nanjing) Co., Ltd. Solid form of compound
WO2023020291A1 (zh) * 2021-08-16 2023-02-23 应世生物科技(南京)有限公司 In10018与pld的联用
US12084453B2 (en) 2021-12-10 2024-09-10 Incyte Corporation Bicyclic amines as CDK12 inhibitors
CN118369120A (zh) 2021-12-10 2024-07-19 应世生物科技(南京)有限公司 治疗肿瘤的药物组合及用途
WO2023116527A1 (zh) 2021-12-21 2023-06-29 微境生物医药科技(上海)有限公司 作为fak抑制剂的化合物及其用途
JP2025507732A (ja) 2022-02-28 2025-03-21 ウィゲン・バイオメディシン・テクノロジー・（シャンハイ）・カンパニー・リミテッド Ｆａｋ阻害剤としての化合物およびその使用
WO2023246869A1 (zh) * 2022-06-24 2023-12-28 应世生物科技(南京)有限公司 治疗肿瘤的药物组合及用途
CN117462553A (zh) * 2022-07-20 2024-01-30 益方生物科技(上海)股份有限公司 药物组合产品以及组合疗法
WO2024041527A1 (zh) * 2022-08-24 2024-02-29 应世生物科技(南京)有限公司 Fak抑制剂及微管抑制剂的药物组合及用途
CN118580221A (zh) * 2023-03-02 2024-09-03 应世生物科技(南京)有限公司 化合物的固体形式

Family Cites Families (37)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9705361D0 (en) * 1997-03-14 1997-04-30 Celltech Therapeutics Ltd Chemical compounds
DE69933680T2 (de) 1998-08-29 2007-08-23 Astrazeneca Ab Pyrimidine verbindungen
US6906067B2 (en) * 1999-12-28 2005-06-14 Bristol-Myers Squibb Company N-heterocyclic inhibitors of TNF-α expression
GB0004890D0 (en) * 2000-03-01 2000-04-19 Astrazeneca Uk Ltd Chemical compounds
GB0004888D0 (en) * 2000-03-01 2000-04-19 Astrazeneca Uk Ltd Chemical compounds
GB0004886D0 (en) * 2000-03-01 2000-04-19 Astrazeneca Uk Ltd Chemical compounds
GB0016877D0 (en) 2000-07-11 2000-08-30 Astrazeneca Ab Chemical compounds
UY27487A1 (es) 2001-10-17 2003-05-30 Boehringer Ingelheim Pharma Derivados de pirimidina, medicamentos que contienen estos compuestos, su empleo y procedimiento para su preparación
MY141867A (en) 2002-06-20 2010-07-16 Vertex Pharma Substituted pyrimidines useful as protein kinase inhibitors
US7504410B2 (en) 2002-11-28 2009-03-17 Schering Aktiengesellschaft Chk-, Pdk- and Akt-inhibitory pyrimidines, their production and use as pharmaceutical agents
JP4634367B2 (ja) 2003-02-20 2011-02-16 スミスクライン ビーチャム コーポレーション ピリミジン化合物
CL2004000306A1 (es) * 2003-02-20 2005-04-08 Tibotec Pharm Ltd Compuestos derivados de pirimidina sustituidas con indano; proceso para su preparacion; composicion farmaceutica que lo comprende; combinacion farmaceutica; y su uso para el tratamiento o profilaxis de una enfermedad infecciosa.
GB0305929D0 (en) 2003-03-14 2003-04-23 Novartis Ag Organic compounds
US7504396B2 (en) * 2003-06-24 2009-03-17 Amgen Inc. Substituted heterocyclic compounds and methods of use
EP1660458B1 (en) 2003-08-15 2012-01-25 Novartis AG 2, 4-pyrimidinediamines useful in the treatment of neoplastic diseases, inflammatory and immune system disorders
EP1598343A1 (de) 2004-05-19 2005-11-23 Boehringer Ingelheim International GmbH 2-Arylaminopyrimidine als PLK Inhibitoren
US7521457B2 (en) * 2004-08-20 2009-04-21 Boehringer Ingelheim International Gmbh Pyrimidines as PLK inhibitors
GB0419160D0 (en) * 2004-08-27 2004-09-29 Novartis Ag Organic compounds
EP1797048B1 (en) 2004-09-30 2011-08-17 Tibotec Pharmaceuticals Hiv inhibiting 5-carbo- or heterocyclic substituted pyrimidines
AU2006204752A1 (en) 2005-01-14 2006-07-20 Neurogen Corporation Heteroaryl substituted quinolin-4-ylamine analogues
US20070032514A1 (en) 2005-07-01 2007-02-08 Zahn Stephan K 2,4-diamino-pyrimidines as aurora inhibitors
US20090149467A1 (en) 2005-09-15 2009-06-11 Merck & Co., Inc. Tyrosine Kinase Inhibitors
US20080318989A1 (en) * 2005-12-19 2008-12-25 Burdick Daniel J Pyrimidine Kinase Inhibitors
FR2896503B1 (fr) 2006-01-23 2012-07-13 Aventis Pharma Sa Nouveaux derives soufres d'uree cyclique, leur preparation et leur utilisation pharmaceutique comme inhibiteurs de kinases
US7569561B2 (en) * 2006-02-22 2009-08-04 Boehringer Ingelheim International Gmbh 2,4-diaminopyrimidines useful for treating cell proliferation diseases
DE602007008545D1 (de) 2006-03-31 2010-09-30 Janssen Pharmaceutica Nv Benzoimidazol-2-yl pyridine und pyrazine als modulatoren des histamin-h4-rezeptors
GB0619343D0 (en) 2006-09-30 2006-11-08 Vernalis R&D Ltd New chemical compounds
WO2008040951A1 (en) 2006-10-03 2008-04-10 Astrazeneca Ab Compounds
CN101553483B (zh) 2006-12-13 2013-04-17 弗·哈夫曼-拉罗切有限公司 作为非核苷逆转录酶抑制剂的2-(哌啶-4-基)-4-苯氧基-或苯基氨基-嘧啶衍生物
CA2670645A1 (en) * 2006-12-19 2008-07-03 Genentech, Inc. Pyrimidine kinase inhibitors
EP2114900B1 (en) * 2007-01-31 2018-10-10 YM BioSciences Australia Pty Ltd Thiopyrimidine-based compounds and uses thereof
PL2154967T3 (pl) * 2007-04-16 2014-08-29 Hutchison Medipharma Entpr Ltd Pochodne pirymidyny
EP2268621A1 (en) 2008-03-20 2011-01-05 Boehringer Ingelheim International GmbH Regioselective preparation of substituted pyrimidines
RU2536584C2 (ru) 2008-06-27 2014-12-27 Авила Терапьютикс, Инк. Гетероарильные соединения и их применение
TWI491605B (zh) 2008-11-24 2015-07-11 Boehringer Ingelheim Int 新穎化合物
AR074209A1 (es) 2008-11-24 2010-12-29 Boehringer Ingelheim Int Derivados de pirimidina utiles para el tratamiento del cancer
EP2440559B1 (en) 2009-05-05 2018-01-10 Dana-Farber Cancer Institute, Inc. Egfr inhibitors and methods of treating disorders

Also Published As

Publication number Publication date
EP2367800B9 (en) 2021-10-20
CN102292322B (zh) 2015-11-25
CN102292322A (zh) 2011-12-21
ECSP11011079A (es) 2011-06-30
JP2012509864A (ja) 2012-04-26
TW201026682A (en) 2010-07-16
NZ592925A (en) 2013-04-26
UY32259A (es) 2010-06-30
GEP20146072B (en) 2014-04-10
IL212814A0 (en) 2011-07-31
WO2010058032A3 (en) 2010-07-15
CA2744351C (en) 2017-07-04
KR101710058B1 (ko) 2017-02-24
US8846689B2 (en) 2014-09-30
TWI491605B (zh) 2015-07-11
ES2664499T9 (es) 2022-01-03
MX337116B (es) 2016-02-12
CA2744351A1 (en) 2010-05-27
US20140371205A1 (en) 2014-12-18
ES2664499T3 (es) 2018-04-19
US20160362404A1 (en) 2016-12-15
CL2011001215A1 (es) 2011-09-30
US20110288071A1 (en) 2011-11-24
MY176944A (en) 2020-08-27
JP5622740B2 (ja) 2014-11-12
AU2009317170B2 (en) 2015-05-28
AP2011005706A0 (en) 2011-06-30
MX2011005420A (es) 2011-06-16
EP2367800A2 (en) 2011-09-28
WO2010058032A2 (en) 2010-05-27
CO6511283A2 (es) 2012-08-31
TN2011000259A1 (en) 2012-12-17
MA32811B1 (fr) 2011-11-01
BRPI0922801A2 (pt) 2020-08-04
CN104478865B (zh) 2017-09-22
HK1160841A1 (zh) 2012-08-17
US20150376141A1 (en) 2015-12-31
CN104478865A (zh) 2015-04-01
AU2009317170A1 (en) 2010-05-27
IL212814B (en) 2018-05-31
EA021997B1 (ru) 2015-10-30
AR074210A1 (es) 2010-12-29
EP2367800B1 (en) 2018-02-28
US9676762B2 (en) 2017-06-13
EA201100794A1 (ru) 2012-01-30
AP2960A (en) 2014-08-31
BRPI0922801B1 (pt) 2021-12-21
KR20110084551A (ko) 2011-07-25

Similar Documents

Publication Publication Date Title
PE20120034A1 (es) Compuestos derivados de n-fenilpirimidin-2-amina
PE20200292A1 (es) Compuestos de heteroarilo biciclicos 6-6 fusionados y su uso como inhibidores de lats
PE20140975A1 (es) Derivados de imidazopirazina como inhibidores de syk
PE20100138A1 (es) Derivados de morfolino pirimidina usados en enfermedades relacionadas en mtor quinasa y/o pi3k
PE20131143A1 (es) Nuevas aminopirazoloquinazolinas
CO5611147A2 (es) Derivados de nicotinamida utiles como inhibidores p38
PE20181269A1 (es) Agonistas del receptor de apelina y metodos de uso
PE20181487A1 (es) Heteroarilhidroxipirimidinonas como agonistas del receptor de apelina (apj)
PE20121500A1 (es) 2-amino-5,5-difluor-5,6-dihidro-4h-oxazinas como inhibidores de bace 1 y/o bace 2
PE20121282A1 (es) Antagonistas de espiro-oxindol de mdm2
PE20050951A1 (es) Compuestos mimeticos de glucocorticoides, metodos de preparacion y composiciones farmaceuticas
CY1113642T1 (el) Γεφυρωμενες δικυκλικες ετεροαρυλ υποκατεστημενες τριαζολες, χρησιμες ως αναστολεις της axl
PE20140927A1 (es) Compuestos heterociclicos como inhibidores de cinasas
CR20110049A (es) Derivados de benzazepina y su uso como antagonistas de histamina h3
NO20050429L (no) Substituert kinolin-CCR5-reseptorantagonister
PE20130155A1 (es) Derivados de ariletinilo
ATE517897T1 (de) Heterobicyclische inhibitoren von hvc
MX2015015893A (es) 2-fenilimidazo[1,2-a]pirimidinas como agentes formadores de imagen.
PE20091466A1 (es) Derivados de 4,5-dihidro-oxazol-2-il-amina
UY31126A1 (es) Derivados de quinoxalina como inhibidores de la actividad de cinasa de tirosina de las cinasas janus
PE20120224A1 (es) Derivados de 1h-imidazo-[4,5-c]-quinolinona
PE20090714A1 (es) Imidazopiridazinas y pirrolo-pirimidinas sustituidas como inhibidores de cinasa de lipido
PE20091849A1 (es) Compuestos y composiciones como inhibidores de cinasa
AR070130A1 (es) Compuestos moduladores de beta-amiloide, un proceso para su obtencion, el uso del compuesto para la fabricacion de un medicamento y dicho medicamento
PE20141827A1 (es) Inhibidores de proteinas quinasas

Legal Events

Date Code Title Description
FG Grant, registration